Literature DB >> 26299414

Outcomes and Factors Associated With Reduced Symptoms in Patients With Gastroparesis.

Pankaj J Pasricha1, Katherine P Yates2, Linda Nguyen3, John Clarke2, Thomas L Abell4, Gianrico Farrugia5, William L Hasler6, Kenneth L Koch7, William J Snape8, Richard W McCallum9, Irene Sarosiek9, James Tonascia2, Laura A Miriel2, Linda Lee2, Frank Hamilton10, Henry P Parkman11.   

Abstract

BACKGROUND & AIMS: Gastroparesis is a chronic clinical syndrome characterized by delayed gastric emptying. However, little is known about patient outcomes or factors associated with reduction of symptoms.
METHODS: We studied adult patients with gastroparesis (of diabetic or idiopathic type) enrolled in the National Institute of Diabetes and Digestive and Kidney Diseases Gastroparesis Clinical Research Consortium Gastroparesis Registry, seen every 16 weeks and treated according to the standard of care with prescribed medications or other therapies at 7 tertiary care centers. Characteristics associated with reduced symptoms, based on a decrease of 1 or more in the gastroparesis cardinal symptom index (GCSI) score after 48 weeks of care, were determined from logistic regression models. Data were collected from patients for up to 4 years (median, 2.1 y).
RESULTS: Of 262 patients, 28% had reductions in GCSI scores of 1 or more at 48 weeks. However, there were no significant reductions in GCSI score from weeks 48 through 192. Factors independently associated with reduced symptoms at 48 weeks included male sex, age 50 years and older, initial infectious prodrome, antidepressant use, and 4-hour gastric retention greater than 20%. Factors associated with no reduction in symptoms included overweight or obesity, a history of smoking, use of pain modulators, moderate to severe abdominal pain, a severe gastroesophageal reflex, and moderate to severe depression.
CONCLUSIONS: Over a median follow-up period of 2.1 years, 28% of patients treated for gastroparesis at centers of expertise had reductions in GCSI scores of 1 or greater, regardless of diabetes. These findings indicate the chronic nature of gastroparesis. We identified factors associated with reduced symptoms that might be used to guide treatment. ClinicalTrials.gov no: NCT00398801.
Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Etiology; GpCRC; Improvement; Predictors

Mesh:

Year:  2015        PMID: 26299414      PMCID: PMC4663150          DOI: 10.1053/j.gastro.2015.08.008

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  48 in total

1.  Gastroesophageal reflux disease presenting with intractable nausea.

Authors:  R J Brzana; K L Koch
Journal:  Ann Intern Med       Date:  1997-05-01       Impact factor: 25.391

2.  The impact of epilepsy on health status among younger and older adults.

Authors:  Mary Jo V Pugh; Laurel A Copeland; John E Zeber; Joyce A Cramer; Megan E Amuan; Jose E Cavazos; Lewis E Kazis
Journal:  Epilepsia       Date:  2005-11       Impact factor: 5.864

3.  Pain: the overlooked symptom in gastroparesis.

Authors:  W A Hoogerwerf; P J Pasricha; A N Kalloo; M M Schuster
Journal:  Am J Gastroenterol       Date:  1999-04       Impact factor: 10.864

4.  Cross-cultural development and validation of a patient self-administered questionnaire to assess quality of life in upper gastrointestinal disorders: the PAGI-QOL.

Authors:  Christine de la Loge; Elyse Trudeau; Patrick Marquis; Peter Kahrilas; Vincenzo Stanghellini; Nicholas J Talley; Jan Tack; Dennis A Revicki; Anne M Rentz; Dominique Dubois
Journal:  Qual Life Res       Date:  2004-12       Impact factor: 4.147

5.  Assessment of gastric emptying using a low fat meal: establishment of international control values.

Authors:  G Tougas; E Y Eaker; T L Abell; H Abrahamsson; M Boivin; J Chen; M P Hocking; E M Quigley; K L Koch; A Z Tokayer; V Stanghellini; Y Chen; J D Huizinga; J Rydén; I Bourgeois; R W McCallum
Journal:  Am J Gastroenterol       Date:  2000-06       Impact factor: 10.864

6.  Clinical features of idiopathic gastroparesis vary with sex, body mass, symptom onset, delay in gastric emptying, and gastroparesis severity.

Authors:  Henry P Parkman; Katherine Yates; William L Hasler; Linda Nguyen; Pankaj J Pasricha; William J Snape; Gianrico Farrugia; Kenneth L Koch; Thomas L Abell; Richard W McCallum; Linda Lee; Aynur Unalp-Arida; James Tonascia; Frank Hamilton
Journal:  Gastroenterology       Date:  2010-10-20       Impact factor: 22.682

7.  Cellular changes in diabetic and idiopathic gastroparesis.

Authors:  Madhusudan Grover; Gianrico Farrugia; Matthew S Lurken; Cheryl E Bernard; Maria Simonetta Faussone-Pellegrini; Thomas C Smyrk; Henry P Parkman; Thomas L Abell; William J Snape; William L Hasler; Aynur Ünalp-Arida; Linda Nguyen; Kenneth L Koch; Jorges Calles; Linda Lee; James Tonascia; Frank A Hamilton; Pankaj J Pasricha
Journal:  Gastroenterology       Date:  2011-02-04       Impact factor: 22.682

8.  Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis.

Authors:  I Soykan; B Sivri; I Sarosiek; B Kiernan; R W McCallum
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

9.  Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index.

Authors:  D A Revicki; A M Rentz; D Dubois; P Kahrilas; V Stanghellini; N J Talley; J Tack
Journal:  Aliment Pharmacol Ther       Date:  2003-07-01       Impact factor: 8.171

10.  Influence of gastric emptying on gastro-esophageal reflux: a combined pH-impedance study.

Authors:  G Gourcerol; Y Benanni; E Boueyre; A M Leroi; P Ducrotte
Journal:  Neurogastroenterol Motil       Date:  2013-07-12       Impact factor: 3.598

View more
  38 in total

1.  Botulinum Toxin A Improves Symptoms of Gastroparesis.

Authors:  Zachary Wilmer Reichenbach; Steven Stanek; Shyam Patel; Sara Jane Ward; Zubair Malik; Henry P Parkman; Ron Schey
Journal:  Dig Dis Sci       Date:  2019-10-15       Impact factor: 3.199

2.  Ethnic, Racial, and Sex Differences in Etiology, Symptoms, Treatment, and Symptom Outcomes of Patients With Gastroparesis.

Authors:  Henry P Parkman; Goro Yamada; Mark L Van Natta; Katherine Yates; William L Hasler; Irene Sarosiek; Madhusudan Grover; Ron Schey; Thomas L Abell; Kenneth L Koch; Braden Kuo; John Clarke; Gianrico Farrugia; Linda Nguyen; William J Snape; Laura Miriel; James Tonascia; Frank Hamilton; Pankaj J Pasricha; Richard W McCallum
Journal:  Clin Gastroenterol Hepatol       Date:  2018-11-04       Impact factor: 11.382

Review 3.  Childhood gastroparesis is a unique entity in need of further investigation.

Authors:  Liz Febo-Rodriguez; Bruno P Chumpitazi; Robert J Shulman
Journal:  Neurogastroenterol Motil       Date:  2019-08-13       Impact factor: 3.598

Review 4.  Pyloric Therapies for Gastroparesis.

Authors:  Nitin K Ahuja; John O Clarke
Journal:  Curr Treat Options Gastroenterol       Date:  2017-03

Review 5.  Gastroparesis: a turning point in understanding and treatment.

Authors:  Madhusudan Grover; Gianrico Farrugia; Vincenzo Stanghellini
Journal:  Gut       Date:  2019-09-28       Impact factor: 23.059

6.  Relating gastric scintigraphy and symptoms to motility capsule transit and pressure findings in suspected gastroparesis.

Authors:  W L Hasler; K P May; L A Wilson; M Van Natta; H P Parkman; P J Pasricha; K L Koch; T L Abell; R W McCallum; L A Nguyen; W J Snape; I Sarosiek; J O Clarke; G Farrugia; J Calles-Escandon; M Grover; J Tonascia; L A Lee; L Miriel; F A Hamilton
Journal:  Neurogastroenterol Motil       Date:  2017-09-05       Impact factor: 3.598

7.  A Critical Review of the Current Clinical Landscape of Gastroparesis.

Authors:  Chimi L Fosso; Eamonn M M Quigley
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-03

8.  Body weight in patients with idiopathic gastroparesis.

Authors:  Henry P Parkman; Mark Van Natta; Goro Yamada; Madhusudan Grover; Richard W McCallum; Irene Sarosiek; Gianrico Farrugia; Kenneth L Koch; Thomas L Abell; Braden Kuo; Laura Miriel; James Tonascia; Frank Hamilton; Pankaj J Pasricha
Journal:  Neurogastroenterol Motil       Date:  2020-09-15       Impact factor: 3.598

9.  Aprepitant Has Mixed Effects on Nausea and Reduces Other Symptoms in Patients With Gastroparesis and Related Disorders.

Authors:  Pankaj J Pasricha; Katherine P Yates; Irene Sarosiek; Richard W McCallum; Thomas L Abell; Kenneth L Koch; Linda Anh B Nguyen; William J Snape; William L Hasler; John O Clarke; Sameer Dhalla; Ellen M Stein; Linda A Lee; Laura A Miriel; Mark L Van Natta; Madhusudan Grover; Gianrico Farrugia; James Tonascia; Frank A Hamilton; Henry P Parkman
Journal:  Gastroenterology       Date:  2017-10-28       Impact factor: 22.682

10.  Innovative gastric endoscopic muscle biopsy to identify all cell types, including myenteric neurons and interstitial cells of Cajal in patients with idiopathic gastroparesis: a feasibility study (with video).

Authors:  Elizabeth Rajan; Christopher J Gostout; Louis M Wong Kee Song; Lawrence A Szarka; Purna C Kashyap; Thomas C Smyrk; Juliane Bingener; Jodie L Deters; Mary A Knipschield; Cheryl E Bernard; Gianrico Farrugia
Journal:  Gastrointest Endosc       Date:  2016-04-27       Impact factor: 9.427

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.